VERAXA Biotech AG Completes Business Combination, Begins Trading on Nasdaq

VERAXA Biotech AG (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.

VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate. The full press release is available at https://ibn.fm/ka00j.

VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates, visit www.veraxa.com.

Voyager Acquisition Corp. is a special purpose acquisition company with a bold mission to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Its team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. For more information, visit https://www.voyageracq.com. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.

This business combination marks a significant milestone for VERAXA, as it gains access to public capital markets to advance its promising oncology pipeline. The BiTAC platform’s potential to selectively target cancer cells while sparing healthy tissue could address significant unmet medical needs in oncology. The completion of this transaction and the initiation of trading on Nasdaq provide VERAXA with the resources and visibility needed to progress its lead candidates toward clinical trials, potentially offering new treatment options for patients with cancer.